Drug Trial Radar · NCT06741072
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Jun 28, 2026
Primary completion
Jul 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Ohio State University Comprehensive Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and related cancers in healthy volunteers and patients awaiting a solid organ transplant. Currently, patients who receive an organ transplant receive immune suppression therapy which can make it harder for the body to fight infections. This treatment also increases the risk for cancers that are triggered by the EBV. Vaccines made from synthetic peptide (RAKFKQLL) derived from the BZLF1 protein, may help the body build an effective immune response against EBV infections. QS-21, a saponin adjuvant, is a substance from plants that, when given with vaccine therapy, may improve the way the immune system responds to disease. Giving OSU-2131 with QS-21 may help the immune system fight EBV and protect against EBV infection and the cancers that it can cause in patients awaiting solid organ transplants.
Conditions
- Chronic Kidney Disease, Stage 4
- Chronic Kidney Disease, Stage 5
- EBV-Related Lymphoproliferative Disorder
- EBV-Related Malignant Neoplasm
- Post-Transplant Lymphoproliferative Disorder
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Dulbecco''s Phosphate-Buffered SalineDrug
Given SC
Peptide VaccineBiological
Given OSU-2131 SC
QS21Biological
Given SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: From the first administration of treatment until the week 28 visit
- Changes in laboratory parameters and vital signsTime frame: At baseline and up to week 56
- Pre- and post-injection vital signsTime frame: Up to week 4
- Injection site reactionsTime frame: At 10 and/or 60 minutes post injection on weeks 0, 2 and 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.